Abstract
This protocol describes a rapid, precise method for generating sets of embryonic stem (ES) cells or mouse embryonic fibroblasts (MEFs) harboring point mutations in the p53 tumor suppressor gene (officially known as Trp53). The strategy uses cells from the Trp53 (p53-null) 'platform' mouse, which allows site-specific integration of plasmid DNA into the Trp53 locus. Simple PCR protocols identify correctly targeted clones and immunoblots verify re-expression of the protein. We also present protocol modifications needed for efficient recovery of MEF clones expressing p53 constructs that retain wild-type function, including growth at low (3%) oxygen and transient downregulation of p53 regulators to forestall cell senescence of primary MEFs. A library of cell lines expressing various p53 mutants derived from the same population of primary fibroblasts or platform ES cells can be acquired and screened in less than 1 month.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Palmero, E.I., Achatz, M.I., Ashton-Prolla, P., Olivier, M. & Hainaut, P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 22, 64–69 (2010).
Breen, L., Heenan, M., Amberger-Murphy, V. & Clynes, M. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. Anticancer Res. 27, 1361–1364 (2007).
Breen, L., Keenan, J. & Clynes, M. Generation of lung cancer cell line variants by drug selection or cloning. Methods Mol. Biol. 731, 125–133 (2011).
Hollstein, M. et al. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 431, 199–209 (1999).
Cimoli, G. et al. Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim. Biophys. Acta 1705, 103–120 (2004).
Milo, G.E., Shuler, C.F., Lee, H. & Casto, B.C. A conundrum in molecular toxicology: molecular and biological changes during neoplastic transformation of human cells. Cell Biol. Toxicol. 11, 329–345 (1995).
Wei, Q.X., Odell, A.F., van der Hoeven, F. & Hollstein, M. Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle 10, 1261–1270 (2011).
Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
Whibley, C., Pharoah, P.D. & Hollstein, M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95–107 (2009).
Reinbold, M. et al. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 27, 2788–2794 (2008).
Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9, 573–580 (2007).
Luo, J.L. et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320–328 (2001).
Odell, A., Askham, J., Whibley, C. & Hollstein, M. How to become immortal: let MEFs count the ways. Aging (Albany NY) 2, 160–165 (2010).
Whibley, C. et al. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J. Biol. Chem. 285, 11326–11335 (2010).
Millau, J.F., Mai, S., Bastien, N. & Drouin, R. p53 functions and cell lines: have we learned the lessons from the past? Bioessays 32, 392–400 (2010).
vom Brocke, J., Schmeiser, H.H., Reinbold, M. & Hollstein, M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27, 2141–2147 (2006).
Liu, Z. et al. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. USA 101, 2963–2968 (2004).
Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106, 3964–3969 (2009).
Nedelko, T. et al. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumors. Int. J. Cancer 124, 987–990 (2009).
Luo, J.L. et al. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res. 61, 8158–8163 (2001).
Barbaric, I. & Dear, T.N. Culture of murine embryonic stem cells. Methods Mol. Biol. 561, 161–184 (2009).
Feng, L., Hollstein, M. & Xu, Y. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 5, 2812–2819 (2006).
Ozenne, P., Eymin, B., Brambilla, E. & Gazzeri, S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 127, 2239–2247 (2010).
Niwa, H., Ogawa, K., Shimosato, D. & Adachi, K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 460, 118–122 (2009).
Ogawa, K. et al. Activin-Nodal signaling is involved in propagation of mouse embryonic stem cells. J. Cell Sci. 120, 55–65 (2007).
Ramirez, M.A., Pericuesta, E., Yanez-Mo, M., Palasz, A. & Gutierrez-Adan, A. Effect of long-term culture of mouse embryonic stem cells under low oxygen concentration as well as on glycosaminoglycan hyaluronan on cell proliferation and differentiation. Cell Prolif. 44, 75–85 (2011).
Tang, W. et al. Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J. Neurosci. 29, 8621–8629 (2009).
Fernandes, T.G., Diogo, M.M., Fernandes-Platzgummer, A., da Silva, C.L. & Cabral, J.M. Different stages of pluripotency determine distinct patterns of proliferation, metabolism, and lineage commitment of embryonic stem cells under hypoxia. Stem Cell Res. 5, 76–89 (2010).
Powers, D.E., Millman, J.R., Huang, R.B. & Colton, C.K. Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics. Biotechnol. Bioeng. 101, 241–254 (2008).
Acknowledgements
We thank N. Pechlivani, A. Weninger and U. Kloz for technical assistance, and the Yorkshire Cancer Research, the White Rose Foundation and the German Cancer Research Center (Deutsches Krebsforschungszentrum) for funding.
Author information
Authors and Affiliations
Contributions
M.H., A.F.O. and Q.-X.W. designed the experiments; Q.-X.W., A.F.O. and F.v.d.H. conducted the experiments; A.F.O., Q.-X.W. and M.H. analyzed the data; A.F.O. and M.H. supervised the project; A.F.O., M.H. and Q.-X.W. wrote the protocol.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figs. 1
Growth of primary platform MEFs at 3% and 21% O2 conditions (a) Growth rate and (b) proliferation of platform MEFs (plf/plf; CA10 and 182.2) is enhanced by growth at 3% O2. Shown are collated data from 3 independent experiments expressed around the SEM. (PDF 1438 kb)
Supplementary Figs. 2
Transient depletion of Ink4a gene products enhances proliferation of primary platform MEFs. Shown are collated data from 4 independent experiments expressed around the SEM. (PDF 1160 kb)
Supplementary Figs. 3
Functional cell lines are generated following Ink4a siRNA depletion. Analysis of cell lines produced at different O2 tensions following prior Ink4a depletion by immunoblotting. Expression of p21 is restored in cell lines generated with TOP constructs retaining WT p53 function (P72, R72 and S15A) when p16 and p19 are previously depleted. Cells were treated with doxorubicin (4 h, 0.5 µM) prior to lysis for stimulation of serine 15 phosphorylation. (PDF 1902 kb)
Supplementary Figs. 4
Expression of p19 (p19arf; ab80-100) is restored by 7 days post-selection (10 days post-siRNA) in WT p53 (pab1801; sc-98) TOP transfectants grown at 21% O2. Scale bars: 20 µm. (PDF 1676 kb)
Supplementary Fig. 5
Expression of several common markers of pluripotency, Nanog (ab80892), Oct3/4 (sc-5279), Sox2 (ab97959), SSEA1 (ab16285) and Tbx3 (sc-31657) are maintained in ES cells generated to express WT, G245S and A138V p53. Also shown are the parent G1 ES cell line and the heterozygous D2 ES cells. Scale bars: 20 µm. (PDF 3718 kb)
Supplementary Method
Analysis of integrase-mediated cassette exchange by duplex PCR (PDF 18 kb)
Rights and permissions
About this article
Cite this article
Wei, QX., van der Hoeven, F., Hollstein, M. et al. Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc 7, 1145–1160 (2012). https://doi.org/10.1038/nprot.2012.042
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2012.042
This article is cited by
-
A platform for interrogating cancer-associated p53 alleles
Oncogene (2017)
-
A novel role for synaptic acetylcholinesterase as an apoptotic deoxyribonuclease
Cell Discovery (2015)
-
A robust TALENs system for highly efficient mammalian genome editing
Scientific Reports (2014)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.